Prime Medicine Inc. (PRME): Price and Financial Metrics

Prime Medicine Inc. (PRME): $4.59

0.34 (-6.90%)

POWR Rating

Component Grades








Add PRME to Watchlist
Sign Up

Industry: Biotech




#348 of 362

in industry

PRME Price/Volume Stats

Current price $4.59 52-week high $17.20
Prev. close $4.93 52-week low $4.56
Day low $4.56 Volume 912,900
Day high $4.98 Avg. volume 670,252
50-day MA $7.15 Dividend yield N/A
200-day MA $9.16 Market Cap 550.52M

PRME Stock Price Chart Interactive Chart >

PRME Latest News Stream

Event/Time News Detail
Loading, please wait...

PRME Latest Social Stream

Loading social stream, please wait...

View Full PRME Social Stream

Latest PRME News From Around the Web

Below are the latest news stories about PRIME MEDICINE INC that investors may wish to consider to help them evaluate PRME as an investment opportunity.

Better Growth Stock: Archer Aviation or Prime Medicine?

Which of these innovation-themed growth stocks is the better buy?

Yahoo | December 19, 2023

1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years

Cathie Wood, founder and CEO of Ark Invest, has a unique approach to investing. As a result, she hasn't hesitated to buy shares of early-stage innovation companies well ahead of the Wall Street crowd. Wood has been purchasing shares of the pre-clinical gene-editing company for her ARK Genomic Revolution ETF (NYSEMKT: ARKG) since the company's initial public offering (IPO) in October of 2022.

Yahoo | November 30, 2023

Prime Medicine to Present at Upcoming Investor Conferences

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences: Stifel Healthcare Conference: Fireside Chat by Keith Gottesdiener, M.D., President and Chief Executive Officer, on Tuesday, November 14, 2023, at 4:10 p.m. ET in New York, NY.Jefferies London Healthcare C

Yahoo | November 8, 2023

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling st

Yahoo | November 3, 2023

Top 20 Genomics Companies in the World

In this piece, we will take a look at the top 20 genomics companies in the world. If you want to skip our analysis of the genomics industry, then take a look at the Top 5 Genomics Companies in the World. Modern day science has delivered a plethora of advancements that have enabled humans to […]

Yahoo | October 30, 2023

Read More 'PRME' Stories Here

PRME Price Returns

1-mo -37.72%
3-mo -29.38%
6-mo -35.71%
1-year -65.72%
3-year N/A
5-year N/A
YTD -48.19%
2023 -52.31%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!